8-K: Tempest Therapeutics Secures R&D Services, Appoints New CFO and Director

Tempest Therapeutics announces a Master Services Agreement with Factor Bioscience Inc. for R&D services, appoints Nancy Freda-Smith to its board, and names Constance Ames as CFO.

Summary

• Tempest Therapeutics entered into a Master Services Agreement (MSA) with Factor Bioscience Inc. on September 22, 2026, for research and development services.
• The MSA supports Tempest's development activities, including its obligations under a prior license and collaboration agreement with Factor Bioscience Limited.
• Work Order No. 1 under the MSA focuses on the development of in vivo CAR-T therapies.
• The company appointed Ms. Nancy Freda-Smith as a Class III director and Chair of the Audit Committee, effective September 22, 2026.
• Mr. Nicholas Rossettos resigned as Chief Financial Officer, and Ms. Constance Ames was appointed as the new CFO, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, effective immediately on September 22, 2026.
• The company expects aggregate fees to Factor Bioscience under the MSA to be $5.0 million per year, plus reimbursement for materials and a 10% project management fee.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, marked by a significant operational agreement and key leadership appointments, balanced by the inherent risks of clinical-stage biotechnology.

Positives

• Secured a Master Services Agreement with Factor Bioscience Inc. to support critical R&D activities for in vivo CAR-T therapies.
• Strengthened the Board of Directors with the appointment of Nancy Freda-Smith, an experienced executive with expertise in corporate governance, finance, and risk management.
• Appointed Constance Ames as CFO, bringing significant experience in corporate finance and accounting for public and private biopharma companies, including IPOs and financings.
• The appointment of Ms. Freda-Smith and other recent board additions are expected to bring the company into compliance with Nasdaq Listing Rules.
• The MSA terms were reviewed and approved by the Audit Committee, ensuring they are no less favorable than terms available from unaffiliated third parties.

Negatives

• The company's former CFO, Nicholas Rossettos, resigned effective immediately.
• The company was previously notified by Nasdaq of non-compliance with listing rules due to board vacancies, though recent appointments aim to rectify this.
• The agreement with Factor Bioscience involves a significant annual commitment of $5.0 million, plus additional costs for materials and project management.

Risks

• The company requires additional capital to fund its planned programs and operations and to continue as a going concern.
• Unexpected safety or efficacy data observed during preclinical or clinical trials could adversely affect development.
• Results from prior clinical trials and preclinical studies may not be predictive of future results.
• Clinical trial site activation or enrollment rates may be lower than expected.
• Loss of key personnel could impact operations.
• Changes in expected or existing competition could affect market position.
• Changes in the regulatory environment could impact development and approval timelines.
• Volatility and uncertainty in capital markets for biotechnology companies pose financial risks.

Future Outlook

The filing does not contain specific forward-looking financial guidance but highlights ongoing development activities for in vivo CAR-T therapies and efforts to regain compliance with Nasdaq listing rules.

Management Comments

• "We are delighted to welcome Nancy to our board. As an experienced board director and C-suite executive who has both led and advised global Fortune 500 companies, Nancy brings deep expertise in corporate governance, global finance, enterprise risk management, and large-scale transformation. Her strategic and operational acumen, along with experience spearheading financial and governance frameworks to support corporate objectives, will bring significant value to Tempest."
• "Tempests science and its differentiated approach to in vivo CAR-T are genuinely compelling, and Im encouraged by the companys efforts to broaden its pipeline and strategic partnerships, creating additional avenues for value creation. I look forward to bringing rigorous financial oversight and governance discipline to the board as Tempest works to execute on this next chapter, and to supporting the team in pursuit of that potential."

Industry Context

StockSavvy.ai notes that the agreement with Factor Bioscience Inc. aligns with the broader trend in the biotechnology sector of strategic partnerships and outsourcing for specialized research and development services, particularly in complex areas like in vivo CAR-T therapies. The focus on strengthening governance and finance functions is also a common theme for clinical-stage companies navigating growth and regulatory scrutiny.

Management Changes

Corporate Governance

Related Party Transactions

• Master Services Agreement (MSA) between Tempest Therapeutics and Factor Bioscience Inc. for research and development services. Dr. Matt Angel, CEO of Tempest, is the majority owner, CEO, and chairman of Factor Bioscience LLC, the parent of Factor Bioscience Inc. The MSA was reviewed and approved by Tempest's Audit Committee, with Dr. Angel not participating.

Stakeholder Impact

• Shareholders: Potential positive impact from strengthened R&D capabilities and improved corporate governance, but also ongoing risk related to the need for future capital.
• Employees: Potential for continued employment and project involvement under the new R&D services agreement; potential impact from CFO transition.
• Creditors: No immediate direct impact, but ongoing financial health and capital needs remain a consideration.
• Suppliers: No direct impact mentioned, but the MSA may influence procurement of certain R&D-related materials and services.

Next Steps

• Continue development of in vivo CAR-T therapies under the MSA with Factor Bioscience Inc.
• Implement services and reporting as per Work Order No. 1.
• Maintain compliance with Nasdaq Listing Rules following board reconstitution.
• Integrate new CFO and director into company operations and governance.

Key Dates

Recommendation

The filing indicates progress in R&D through a significant services agreement and strengthening of the board and finance leadership. However, the company's inherent clinical-stage risks and the previously disclosed need for additional capital suggest a 'hold' recommendation pending further clinical data and financial developments.

Keywords

in vivo CAR-T, Master Services Agreement, biotechnology, drug development, clinical-stage, corporate governance, finance, audit committee